<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714216</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001835</org_study_id>
    <nct_id>NCT04714216</nct_id>
  </id_info>
  <brief_title>Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility</brief_title>
  <official_title>Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Insulet Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-arm stepwise feasibility study will test initial deployment of hybrid closed-loop&#xD;
      (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote&#xD;
      monitoring and device operation capabilities to hospitalized patients admitted to the general&#xD;
      medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-arm stepwise feasibility study will test initial deployment of hybrid closed-loop&#xD;
      (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote&#xD;
      monitoring and device operation capabilities to hospitalized patients admitted to the general&#xD;
      medical/surgical floorwith diabetes (type 1 or type 2) requiring insulin therapy. All&#xD;
      enrolled participants will be placed on HCL insulin therapy for 10 days or until hospital&#xD;
      discharge (if less than 10 days) to determine functional operability of the system and its&#xD;
      effect on glycemic control in the hospital setting. This study will generate preliminary data&#xD;
      to inform the design of a large multi-institution randomized controlled trial to assess&#xD;
      superiority of HCL compared to standard inpatient insulin therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of time spent in HCL after CGM sensor meets initial validation criteria</measure>
    <time_frame>Up to 10 days until hospital discharge</time_frame>
    <description>Proportion of time spent in HCL after CGM sensor meets initial validation criteria [sensor glucose value is within ±20% of POC values (for glucose levels ≥70 mg/dL) or ±20 mg/dL for POC glucose values &lt;70 mg/dL].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of time sensor glucose is within target glucose range</measure>
    <time_frame>Up to 10 days until hospital discharge</time_frame>
    <description>Percentage of time sensor glucose is within target glucose range [time-in-range (TIR)], defined as 70-180 mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from enrollment to start of HCL therapy (after initial CGM validation)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Time from enrollment to start of HCL therapy (after initial CGM validation) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time with CGM readings</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percentage of time with CGM readings will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CGM values meeting accuracy criteria for bolus/correction insulin dosing</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percentage of CGM values meeting accuracy criteria for bolus/correction insulin dosing will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CGM readings within %15/15 of POC readings and within %20/20 of POC readings with the cut point at 70 mg/dL</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Number of CGM readings within %15/15 of POC readings and within %20/20 of POC readings with the cut point at 70 mg/dL will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic (&lt;70 mg/dL) episodes per patient</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Number of hypoglycemic (&lt;70 mg/dL) episodes per patient will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number clinically important hypoglycemic (&lt;54 mg/dL) episodes per patient</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Number clinically important hypoglycemic (&lt;54 mg/dL) episodes per patient will recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time below range (TBR, &lt;70mg/dL)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percent time below range (TBR, &lt;70mg/dL) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time below range (&lt;54 mg/dL)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percent time below range (&lt;54 mg/dL) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time above range (TAR, &gt;180 mg/dL)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percent time above range (TAR, &gt;180 mg/dL) will be recoreded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time in severe hyperglycemia (&gt;250 mg/dL)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Percent time in severe hyperglycemia (&gt;250 mg/dL) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting overall adjustments for clinically-important hypoglycemia (&lt;54 mg/dL)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting overall adjustments for clinically-important hypoglycemia (&lt;54 mg/dL) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL)to basal rate</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL)to basal rate will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL) to insulin carb ratio (ICR)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL) to insulin carb ratio (ICR) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL)to insulin sensitivity factor (ISF)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for clinically-important hypoglycemia (&lt;54 mg/dL)to insulin sensitivity factor (ISF) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting overall adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting overall adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to basal rate</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to basal rate will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to ICR</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to ICR will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to ISF</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Frequency of setting adjustments for prolonged hyperglycemia (&gt;250 mg/dL for &gt;1 hour) to ISF will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily insulin (TDI)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Total daily insulin (TDI) will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily basal insulin (TBI)</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Total daily basal insulin (TBI) will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily bolus meal/correction</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Total daily bolus meal/correction will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events that required assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Number of hypoglycemic events that required assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic ketoacidosis events</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Number of Diabetic ketoacidosis events will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survey</measure>
    <time_frame>Until hospital discharge (up to 10 days )</time_frame>
    <description>Patient survey on HCL system use</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hybrid closed-loop (HCL) automated insulin delivery (AID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Omnipod 5/Horizon HCL system</intervention_name>
    <description>The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or &quot;pod&quot;), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments.</description>
    <arm_group_label>Hybrid closed-loop (HCL) automated insulin delivery (AID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years of age with insulin-treated T1 or T2DM admitted to general&#xD;
             (non-intensive care) medical-surgical hospital service requiring inpatient insulin&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients admitted the ICU or anticipated to require ICU transfer&#xD;
&#xD;
          -  Anticipated length of hospital stay &lt;48 hours.&#xD;
&#xD;
          -  Evidence of hyperglycemic crises (diabetic ketoacidosis or hyperosmolar hyperglycemic&#xD;
             state) at enrollment&#xD;
&#xD;
          -  Severely impaired renal function (eGFR &lt; 30 ml/min/1.73m2) or clinically significant&#xD;
             liver failure&#xD;
&#xD;
          -  Severe anemia with hemoglobin &lt;7 g/dL&#xD;
&#xD;
          -  Evidence of hemodynamic instability&#xD;
&#xD;
          -  Hypoxia (SpO2 &lt;95% on supplemental oxygen)&#xD;
&#xD;
          -  Pre-admission or inpatient total daily insulin dose &gt;100 units&#xD;
&#xD;
          -  Mental condition rendering the participant unable to consent or answer questionnaires&#xD;
&#xD;
          -  Pregnant or breast feeding at time of enrollment&#xD;
&#xD;
          -  Unable or unwilling to use rapid-acting insulin analogs (Humalog, Admelog, Novolog or&#xD;
             Apidra) during the study&#xD;
&#xD;
          -  Use of hydroxyurea or high-dose ascorbic acid (&gt;1g/day)&#xD;
&#xD;
          -  COVID-19 infection or person under investigation (PUI) on isolation precautions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Pasquel, M.D., M.P.H</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Pasquel, M.D., M.P.H</last_name>
    <phone>4047781695</phone>
    <email>fpasque@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Buckingham, MD</last_name>
      <phone>650-721-1811</phone>
      <email>buckingham@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grady Health System (non-CRN)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Pasquel, MD, MPH</last_name>
      <phone>404-778-1695</phone>
      <email>fpasque@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Georgia Davis, MD</last_name>
      <email>gmdavis@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Brown, MD</last_name>
      <phone>434-924-1825</phone>
      <email>sab2f@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Francisco Pasquel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Automated insulin delivery</keyword>
  <keyword>Hybrid closed-loop system</keyword>
  <keyword>Inpatient insulin therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

